The agonizing itching is one of the most difficult symptoms to bear in patients with primary biliary cholangitis (PBC). It can have a far greater impact on everyday life, sleep and mental stability than the laboratory values of the underlying disease. New studies and congress papers from 2025 show that the therapeutic spectrum has expanded significantly in recent years. The focus today is on the targeted modulation of cholestatic mechanisms, in particular through inhibitors of bile acid transport and PPAR agonists, which not only have a favorable effect on the course of the disease but also on the symptom burden.
Autoren
- Tanja Schliebe
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Case study
Discoid Lupus Erythematosus in a 38-Year-Old Woman
- Hand and Finger Injuries
Preventing Permanent Functional Limitations
- From an antidiabetic drug to a distinct class of cardiorenal therapies
The Incretin Revolution in Cardiology
- Prostate Cancer
Intracrine and Metabolic Tumor Adaptation Under Androgen Deprivation
- Alopecia areata in children, adolescents, and adults
New Guideline Classifies the Evidence Base for Topical and Systemic Therapies
- Cardiology and Nutrition
Ultra-Processed Foods and Cardiovascular Risk—The New AHA Position
- Actinic keratoses
Targeted Treatment of Multiple AK Lesions—Balancing Efficacy and Convenience
- Obesity: A Multimodal and Interdisciplinary Approach